ACADIA Pharmaceuticals Inc (ACAD)vsModerna Inc (MRNA)
ACAD
ACADIA Pharmaceuticals Inc
$27.83
+0.32%
HEALTHCARE · Cap: $4.77B
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 96% more annual revenue ($2.23B vs $1.14B). ACAD leads profitability with a 33.4% profit margin vs -141.4%. ACAD earns a higher WallStSmart Score of 61/100 (C+).
ACAD
Buy61
out of 100
Grade: C+
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACAD.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 30 in profit
Keeps 33 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Attractively priced relative to earnings
16.4% revenue growth
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ACAD
The strongest argument for ACAD centers on Return on Equity, Profit Margin, Debt/Equity. Profitability is solid with margins at 33.4% and operating margin at 12.3%. Revenue growth of 16.4% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ACAD
The primary concerns for ACAD are PEG Ratio.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ACAD profiles as a growth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
ACAD is growing revenue faster at 16.4% — sustainability is the question.
ACAD generates stronger free cash flow (124M), providing more financial flexibility.
Bottom Line
ACAD scores higher overall (61/100 vs 21/100), backed by strong 33.4% margins and 16.4% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ACADIA Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?